SEC Comment Letter for Ayala Pharmaceuticals, Inc. (CIK 0001797336) — Jun 10, 2021
Ayala Pharmaceuticals, Inc. (CIK 0001797336)
Date: June 10, 2021 · CIK: 0001797336 · Accession: 0000000000-21-007199
AI Filing Summary & Sentiment
File numbers found in text: 333-256792
Letter
United States securities and exchange commission logo June 10, 2021 Roni Mamluk, Ph.D. Chief Executive Officer Ayala Pharmaceuticals, Inc. 1313 N. Market Street, Suite 5100 Wilmington, DE 19801 Re:Ayala Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 4, 2021 File No. 333-256792 Dear Dr. Mamluk: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Keith L. Halverstam, Esq.
Show Raw Text
United States securities and exchange commission logo
June 10, 2021
Roni Mamluk, Ph.D.
Chief Executive Officer
Ayala Pharmaceuticals, Inc.
1313 N. Market Street, Suite 5100
Wilmington, DE 19801
Re:Ayala Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 4, 2021
File No. 333-256792
Dear Dr. Mamluk:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Keith L. Halverstam, Esq.